Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Original ArticlesMineral Metabolism and Bone Disease
You have accessRestricted Access

Cholecalciferol Supplementation in Hemodialysis Patients: Effects on Mineral Metabolism, Inflammation, and Cardiac Dimension Parameters

Patrícia João Matias, Cristina Jorge, Carina Ferreira, Marília Borges, Inês Aires, Tiago Amaral, Célia Gil, José Cortez and Aníbal Ferreira
CJASN May 2010, 5 (5) 905-911; DOI: https://doi.org/10.2215/CJN.06510909
Patrícia João Matias
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cristina Jorge
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carina Ferreira
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marília Borges
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Inês Aires
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tiago Amaral
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Célia Gil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
José Cortez
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aníbal Ferreira
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Abstract

Background and objectives: Vitamin D deficiency is highly prevalent in chronic kidney disease. The aim of this study was to evaluate the effects of oral cholecalciferol supplementation on mineral metabolism, inflammation, and cardiac dimension parameters in long-term hemodialysis (HD) patients.

Design, setting, participants, & measurements: This 1-year prospective study included 158 HD patients. Serum levels of 25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxyvitamin D [1,25(OH)2D], intact parathyroid hormone, and plasma brain natriuretic peptide as well as circulating bone metabolism and inflammation parameters were measured before and after supplementation. Baseline 25(OH)D and 1,25(OH)2D levels were measured twice (end of winter and of summer, respectively). Therapy with paricalcitol, sevelamer, and darbepoietin was evaluated.

Results: There was an increase in serum 25(OH)D and 1,25(OH)2D levels after supplementation. Conversely, serum calcium, phosphorus, and intact parathyroid hormone were decreased. There was a reduction in the dosage and in the number of patients who were treated with paricalcitol and sevelamer. Darbepoietin use was also reduced, with no modification of hemoglobin values. Serum albumin increased and C-reactive protein decreased during the study. Brain natriuretic peptide levels and left ventricular mass index were significantly reduced at the end of the supplementation.

Conclusions: Oral cholecalciferol supplementation in HD patients seems to be an easy and cost-effective therapeutic measure. It allows reduction of vitamin D deficiency, better control of mineral metabolism with less use of active vitamin D, attenuation of inflammation, reduced dosing of erythropoiesis-stimulating agents, and possibly improvement of cardiac dysfunction.

Patients with chronic kidney disease (CKD) frequently have low serum 25-hydroxyvitamin D [25(OH)D] or calcidiol levels, which is the substrate of 1,25-dihydroxyvitamin D [1,25(OH)2D] or calcitriol (1–3). With CKD progression, this tendency to vitamin D substrate insufficiency, coupled with the demonstrated loss of the renal 1α-hydroxylase activity, leads to progressive calcitriol deficiency (4,5).

Levels of 25(OH)D have been shown to be the best indicator of vitamin D status (6). In some studies (7,8), 25(OH)D showed inverse correlations with age, female gender, diabetes, and intact parathyroid hormone (iPTH) level. Calcidiol concentration also depends on the season, with higher serum levels after summer time (8).

The importance of measuring 25(OH)D levels is also supported by the newly emerging concept that an extrarenal 1α-hydroxylase is expressed in many sites outside the kidney. The extrarenal pool of 1α-hydroxylase (unlike its renal pool) seems to remain intact in kidney disease. This locally produced 1,25(OH)2D seems to have “autocrine or paracrine” effects and to promote additional roles for vitamin D, beyond its classical functions in mineral metabolism. Indeed, studies have demonstrated that 1,25(OH)2D acts as a cell-differentiating factor and antiproliferative agent on a variety of tissues (9–11). By influencing gene expression in multiple tissues, including the immune system, skin, muscle, pancreas, kidney, and brain, it is believed that vitamin D is involved in the pathogenesis of psoriasis, certain types of cancer, multiple sclerosis, diabetes, and BP regulation (9,12). Deficient levels of 25(OH)D have also been associated with cardiovascular risk factors in patients with and without CKD (12–15).

The evaluation of calcidiol serum levels in patients with stage 5D CKD is suggested by the Kidney Disease: Improving Global Outcomes (KDIGO) recommendations, and the proposed strategy for correction of 25(OH)D deficiency/insufficiency is similar to that used in the general population (16). The aim of this study was to evaluate the effects of oral cholecalciferol supplementation in mineral metabolism, inflammation markers, and cardiac dysfunction in patients with stage 5D CKD.

Materials and Methods

Study Design

This was a 1-year follow-up, prospective study of a cohort of prevalent hemodialysis (HD) patients from a single center (two dialysis units sharing the medical team). Serum 25(OH)D and 1,25(OH)2D were measured on two occasions with a 6-month interval (end of winter and of summer, respectively) and at the end of the study, after 6 months of cholecalciferol supplementation.

Population

All patients were included in the study, except for those who were taking cinacalcet, oral calcitriol, or calcium (Ca) carbonate and those who had undergone parathyroidectomy. Patients who were lost to follow-up were also excluded from the analysis (25 patients died, 20 were transferred and six received a transplant).

The study included 158 patients: 74 (47%) men and 84 (53%) women with mean age of 62.8 ± 14.8 years. All patients underwent dialysis with high-flux membranes (helixone-Fresenius) and ultrapure water (evaluated monthly by cinetic chromogenic test). The dialysate Ca concentration was 1.5 mmol/L for all patients during the study. Mean HD vintage was 44.3 ± 32.4 months.

Thirty-nine (25%) patients had diabetes, and 54 (34%) had hypertension. Coronary artery disease was diagnosed when the patient had a typical history of angina pectoris or had sustained a myocardial infarction, had a positive stress test, or had undergone a percutaneous coronary intervention or coronary bypass surgery. According to these criteria, coronary artery disease was diagnosed in 49 (31%) patients.

At baseline, 70 (44%) patients were taking paricalcitol (the only active vitamin D used during the study), at a mean dosage of 7.2 ± 4.5 μg/wk (range 2.5 to 30.0 μg/wk). A total of 145 (92%) patients were on darbepoietin therapy, with a mean dosage of 0.042 μg/kg per wk per g/dl. The target for ferritin was between 200 and 800 ng/ml for all patients, and, when needed, only intravenous iron saccarate was used.

Systolic (SBP) and diastolic BP (DBP) were measured in all HD sessions in the month before the beginning of supplementation and in the last month of cholecalciferol supplementation. Pulse pressure (PP) was also calculated (on the basis of BP measurements before HD) by the formula PP = SBP − DBP. Antihypertensive medication, including angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), and therapy with statins were evaluated at the beginning and at the end of the study.

Oral cholecalciferol (Vigantol) was prescribed once or thrice weekly, after each HD session, ensuring 100% adhesion. Supplementation was started for all patients at the same time and was maintained for 6 months. It was based on baseline calcidiol serum levels: 50,000 IU (2.5 ml, or 75 drops) once a week for patients with 25(OH)D levels <15 ng/ml, 10,000 IU (0.5 ml, or 15 drops) once a week when 25(OH)D was between 16 and 30 ng/ml, and 2700 IU (4 drops) three times per week when levels where >30 ng/ml.

Biochemical Analysis

Serum 25(OH)D and 1,25(OH)2D levels were measured with a RIA provided by IDS (Boldon, UK). After an extraction procedure, the assay is carried out with anti-25(OH)D or anti-1,25(OH)2D ovine antibody, and phase separation is performed with anti-ovine IgG antiserum. The assay measures 25(OH)D2 and 25(OH)D3 or 1,25(OH)2D2 and 1,25(OH)2D3. Intra-assay and interassay variability are 5 and 8%, respectively. The normal range for 25(OH)D is 10 to 60 ng/ml and for 1,25(OH)2D is 20 to 46 pg/ml, as indicated by the manufacturer. The inferior detection limit is 1.6 ng/ml and 2.5 pg/ml, respectively.

Serum Ca, serum phosphorus (P), Ca-P product, total intact parathyroid hormone (iPTH), bone alkaline phosphatase, hemoglobin, ferritin, albumin, and C-reactive protein (CRP) were measured before the beginning of supplementation and at the end of the study. Ca was corrected for hypoalbuminemia by addition of 0.8 mg/dl to the Ca concentration for each 1-g/dl decrease in albumin concentration from 4.0 g/dl (17). Total iPTH was evaluated by immunochemiluminescence using a second-generation assay (Immulite 2000; Siemens Medical Solutions Diagnostics, Los Angeles, CA) and normal range of values is 10 to 65 pg/ml. Albumin was measured using a colorimetric assay and CRP was evaluated by an immunoturbidimetric assay.

The levels of brain natriuretic peptide (BNP) were determined before the beginning of supplementation and at the end of the study in EDTA plasma samples that were collected before HD, using the AxSYM BNP Assay (MEIA) on the AxSYM 2 Immunochemical Analyser (Abbott Laboratories, Chicago, IL). In a previous study (18), we found no significant difference on BNP measured levels before or after dialysis. All blood samples were collected before dialysis in midweek sessions.

Echocardiography Evaluation

At the beginning and at the end of the study, each patient underwent an echocardiography examination, and left ventricular mass index (LVMI) was calculated using the Devereux formula (19) and indexed to body surface area. This examination was performed on a midweek nondialysis day and in the same cardiologic center.

Statistical Analysis

For statistical analysis, the arithmetic mean of the two measurements of 25(OH)D and 1,25(OH)2D at baseline (end of winter and of summer, respectively) was used. Demographic and laboratory data were compared at baseline and after 6 months of cholecalciferol supplementation. Variables were expressed as frequencies for categorical variables, mean values with SD for normally distributed variables, and median (interquartile ranges) values for non-normally distributed variables. Comparison between two groups was performed using paired Wilcoxon test. Spearman correlation was used for univariate analysis.

Statistical analysis was performed with SPSS 15.0 (SPSS Inc., Chicago, IL). P < 0.05 was considered statistically significant.

Results

At baseline, both 25(OH)D and 1,25(OH)2D serum levels were low and positively correlated (r = 0.25, P < 0.001). Serum 25(OH)D was bellow sufficiency values (<30 ng/ml) in almost 80% of our patients, and levels of 1,25(OH)2D were considered insufficient (<20 pg/ml) in >95% of patients. Serum levels of 25(OH)D were higher after summer compared with after winter but were not statistically significant (22.6 ± 16.0 versus 20.8 ± 12.3 ng/ml; P > 0.05). Calcitriol serum levels were similar on both occasions (4.7 versus 4.6 pg/ml; P > 0.05). Older patients showed lower levels of 25(OH)D (r = −0.31, P < 0.001). Patients with diabetics presented lower concentrations of 25(OH)D (24.2 ± 12.5 versus 18.5 ± 9.7 ng/ml; P < 0.001) and 1,25(OH)2D (4.4 versus 4.9 pg/ml; P = 0.02) than patients without diabetes.

Postwinter and postsummer baseline measurements were compared with the values that were obtained after 6 months of oral cholecalciferol supplementation. There was a significant increase in 25(OH)D (22.3 ± 12.0 versus 42.0 ± 12.1 ng/ml; P < 0.001) and 1,25(OH)2D (4.6 versus 5.9 pg/ml; P = 0.001) levels (Figure 1). In 136 (86%) patients, 25(OH)D levels became normal (>30 ng/ml) at the end of the study, in comparison with only 32 (20%) at baseline (Figure 2). Most of the patients whose 25(OH)D levels did not increase had diabetes (P < 0.001). None of the patients achieved a toxic level of 25(OH)D: >100 ng/ml (20).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

25(OH)D and 1,25(OH)2D serum values after winter, after summer, and after cholecalciferol supplementation.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Serum 25(OH)D distribution before and after supplementation.

Clinical and biochemical parameters at the beginning and at the end of supplementation are reported in Table 1. Serum Ca (P = 0.014) and P (P = 0.011) showed a significant reduction with supplementation. This was independent of paricalcitol therapy, because patients who were not administered active vitamin D during the studied period also presented this reduction. Levels of iPTH (P = 0.01) showed a significant decrease with supplementation. There were no episodes of hypercalcemia >10.5 mg/dl during the study. Only 11 (7%) patients of those who had iPTH levels between 150 and 300 pg/ml at the beginning of the study showed values <150 pg/ml after supplementation.

View this table:
  • View inline
  • View popup
Table 1.

Clinical, biochemical, and echocardiographic parameters before and after supplementation

In association with the cholecalciferol supplementation, a significant reduction in the number of treated patients as well as in active vitamin D dosage was observed (P < 0.001). Patients who were taking paricalcitol during the study showed significantly lower 1,25(OH)2D levels (3.9 versus 6.8 pg/ml; P < 0.001) despite a same increase in 25(OH)D values (Figure 3). There was also a significant decrease in patients who were treated with sevelamer after supplementation (P < 0.001).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

25(OH)D and 1,25(OH)2D serum levels before and after supplementation in patients without and with paricalcitol therapy.

Darbepoietin use also decreased (P = 0.013), with no modification of hemoglobin and ferritin values. Serum albumin increased (P < 0.001) and CRP decreased (P = 0.004) with supplementation.

Mean SBP, DBP, PP, and interdialytic weight gain in the last month before supplementation and in the last month of supplementation were similar. The percentage of patients who were on antihypertensive therapy, namely ACEIs and ARBs, and treated with statins was not different at the beginning and at the end of the study.

Although BNP plasma levels were high compared with the general population with no cardiac disease, they showed a significant reduction during the study (P = 0.008). LVMI also had a significant decrease after supplementation (P = 0.01). There was a significant negative correlation between the percentage of change in 25(OH)D and the percentage of change in BNP levels (r = −0.21, P = 0.009) and LVMI (r = −0.24, P = 0.003; Figure 4). The percentage of change in BNP was also positively correlated with the percentage of change in LVMI (r = 0.19, P = 0.02).

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Correlations between the percentage of change in 25(OH)D and the percentage of change in BNP and LVMI with cholecalciferol supplementation.

Discussion

Our study confirms the high incidence of vitamin D deficiency or insufficiency in HD patients and the apparently safety and efficacy of oral supplementation with native vitamin D. Patients with stage 5 CKD lack the capacity of the kidney to perform 1α-hydroxylation, thereby making it impossible to produce the necessary amount of 1,25(OH)2D. Studies have also described the presence of a phosphaturic bone protein fibroblast growth factor 23 that is elevated in patients with CKD and may amplify the inhibition of renal 1α-hydroxylase (11,21); however, extrarenal production of 1,25(OH)2D in anephric patients has been reported (22). Also, it was recently described that calcitriol levels in HD patients increased after 6 months of supplementation with 25(OH)D (23).

The expression of 1α-hydroxylase was also reported in other organs, such as the parathyroids, pancreas, adrenal medulla, endothelium, smooth vascular cells, skin, and cerebellum (11,24). This may indicate an autocrine/paracrine function of this enzyme in the control of cell proliferation and differentiation (25).

In our study, as already described in other studies, older patients and patients with diabetes showed lower levels of 25(OH)D. Elderly patients have reduced sun exposure as a result of poor health and immobility and have reduced ingestion of natural sources of vitamin D, and dermal synthesis of vitamin D is reduced with increasing age (26,27). In this study, lower levels of 1,25(OH)2D were also present in patients with diabetes, probably reflecting lower production of the substrate. It is interesting that, as we found previously (15), patients who were receiving paricalcitol therapy showed lower levels of 1,25(OH)2D. The exact reason for this is not completely known, but vitamin D2 activates the catabolism of 1,25(OH)2D through the activation of 24-hydroxylase (28). Although this enzyme acts in 25(OH)D and 1,25(OH)2D, it has a 10-fold higher affinity for the latter molecule (29). Another hypothesis is that because paricalcitol acts in vivo as an active vitamin D, the target cell might downregulate the production of 1,25(OH)2D.

An in vitro study also reported that 25(OH)D may directly activate the vitamin D receptor in the parathyroid gland, independent of 1,25(OH)2D, contributing to the control of secondary hyperparathyroidism (30). Our study shows a decrease in Ca and P and an improvement in hyperparathyroidism control after cholecalciferol supplementation. This reduction in serum Ca and P was more significant than the reduction seen in iPTH and was independent of paricalcitol therapy, because patients who never used this medication also showed this reduction. The observed increase in serum albumin may also have contributed to the decrease in Ca levels. The active vitamin D therapeutic dosage was also significantly reduced and might contribute to a less calcemic and phosphoremic action seen at the end of the study. Conversely, lower Ca and P are potent stimulus of 1α-hydroxylase (11,24,25), and that could explain some of the increase in 1,25(OH)2D levels.

The role of vitamin D metabolism has also been involved in the improvement of erythropoiesis by a direct effect on erythroid precursor proliferation (31) and/or, marginally, by controlling secondary hyperparathyroidism (32). In our study, the dosage of the erythroid-stimulating agent was reduced, with no modification of hemoglobin values.

Several studies have shown that vitamin D has numerous important nonclassic actions, including a protective role in innate immunity (33), antiatherosclerotic effects, and normalization of inflammatory reactions (10,11,14). Low vitamin D levels were also associated with decreased pulmonary function test results, increased PP, congestive heart failure, and increased carotid intima-media thickness (25,34). Our study, like others (35,36), indicates a reduction in the inflammatory parameters, with an increase in albumin and a reduction in CRP. This could reflect 25(OH)D as another marker of inflammation or represent the already described immunomodulator and anti-inflammatory actions of this hormone.

Dialysis patients have increased cardiovascular morbidity and mortality (37). BNP plasma levels have been shown to be a good cardiovascular risk marker in the general population as well as in patients with CKD (38,39). Plasma BNP is synthesized mainly in cardiomyocytes in response to ventricular stretch and pressure overload (40), but it may also result from concomitant coronary artery disease or left ventricular dysfunction (41). Studies have indicated that the degree of BNP elevation in patients with CKD may predict left ventricular function and future cardiac events (40–42). In a previous study (18), we also found an increase in cardiovascular morbidity and mortality in HD patients with higher BNP plasma levels. In this study, as reported in other studies, mean BNP plasma levels were high (compared with the general population) as a result of renal failure and in some patients simultaneous cardiac disease, but its levels were significantly decreased after cholecalciferol supplementation.

Vitamin D is also important in the regulation of BP through inhibition of the renin-angiotensin pathway (42), and lower circulating vitamin D levels correlated with increased BP and LVMI (15,43). Our study has shown that the correction of vitamin D deficiency with vitamin D precursors, namely cholecalciferol, can decrease LVMI. This reduction in BNP plasma levels and LVMI with supplementation was independent of PP and of the use of antihypertensive therapy, namely ACEIs and ARBs, and statins.

The main limitation of this study is the absence of a control group. Because the general care and therapeutic approach to these patients did not change during the study, the results were assumed to be due to cholecalciferol supplementation. Other limitations are the short duration of cholecalciferol supplementation, the small number of patients studied, and some drawbacks of echocardiography in evaluating LVMI.

Conclusions

Cholecalciferol supplementation corrected vitamin D deficiency without evident toxicity. It increased mineral metabolism control with less use of active vitamin D, decreased inflammatory parameters with reduction of erythropoiesis-stimulating agent consumption, and improved cardiac dysfunction (reflected by lower BNP levels and decreased LVMI). These effects may be related to the direct action of 25(OH)D on target cells and/or to persistent renal or extrarenal 1α-hydroxylation.

This supplementation was simple, apparently safe, and cost-effective. More important, it seems to be a treatment that positively affects surrogate markers and may potentially improve clinical outcomes. On the basis of this study, we propose cholecalciferol supplementation for patients with stage 5D CKD, although the effects on morbidity and mortality still need to be confirmed in randomized, controlled, and longer follow-up studies.

Disclosures

None.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • Received September 14, 2009.
  • Accepted February 1, 2010.
  • Copyright © 2010 by the American Society of Nephrology

References

  1. 1.↵
    1. Gonzalez EA,
    2. Sachdeva A,
    3. Oliver DA,
    4. Martin KJ
    : Vitamin D insufficiency and deficiency in chronic kidney disease: A single center observational study. Am J Nephrol 24: 503– 510, 2004
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. LaClair RE,
    2. Hellman RN,
    3. Karp SL,
    4. Kraus M,
    5. Ofner S,
    6. Li Q,
    7. Graves KL,
    8. Moe SM
    : Prevalence of calcidiol deficiency in CKD: A cross-sectional study across latitudes in the United States. Am J Kidney Dis 45: 1026– 1033, 2005
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Ishimura E,
    2. Nishizawa Y,
    3. Inaba M,
    4. Matsumoto N,
    5. Emoto M,
    6. Kawagishi T,
    7. Shoji S,
    8. Okuno S,
    9. Kim M,
    10. Miki T,
    11. Morii H
    : Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialysed patients with chronic renal failure. Kidney Int 55: 1019– 1027, 1999
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Goodman WG,
    2. Coburn JW
    : The use of 1,25-dihydroxyvitamin D3 in early renal failure. Annu Rev Med 43: 227– 237, 1992
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Schroeder NJ,
    2. Cunningham J
    : What's new in vitamin D for the nephrologist? Nephrol Dial Transplant 15: 460– 466, 2000
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Slatopolsky E,
    2. Weerts C,
    3. Thielan J,
    4. Horst R,
    5. Harter H,
    6. Martin KJ
    : Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 74: 2136– 2143, 1984
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Gomez-Alonso C,
    2. Naves-Diaz ML,
    3. Fernandez-Martin JL,
    4. Diaz-Lopez JB,
    5. Fernandez-Coto MT,
    6. Cannata-Andia JB
    : Vitamin D status and secondary hyperparathyroidism: The importance of 25-hydroxyvitamin D cut-off levels. Kidney Int Suppl S44– S48, 2003
  8. 8.↵
    1. Lagunova Z,
    2. Porojnicu AC,
    3. Lindberg F,
    4. Hexeberg S,
    5. Moan J
    : The dependency of vitamin D status on body mass index, gender, age and season. Anticancer Res 29: 3713– 3720, 2009
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Holick MF
    : Vitamin D: Importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr 79: 362– 371, 2004
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Andress DL
    : Vitamin D in chronic kidney disease: A systemic role for selective vitamin D receptor activation. Kidney Int 69: 33– 43, 2006
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Jones G
    : Expanding role for vitamin D in chronic kidney disease: Importance of blood 25-OH-D levels and extra-renal 1α-hydroxylase in the classical and non-classical actions of 1α,25-dihydroxyvitamin D3. Semin Dial 20: 316– 324, 2007
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Kristal-Boneh E,
    2. Froom P,
    3. Harari G,
    4. Ribak J
    : Association of calcitriol and blood pressure in normotensive men. Hypertension 30: 1289– 1294, 1997
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Zittermann A,
    2. Schleithoff SS,
    3. Tenderich G,
    4. Berthold HK,
    5. Korfer R,
    6. Stehle P
    : Low vitamin D status: A contributing factor in the pathogenesis of congestive heart failure. J Am Coll Cardiol 41: 105– 112, 2003
    OpenUrlPubMed
  14. 14.↵
    1. London GM,
    2. Guérin AP,
    3. Verbeke FH,
    4. Pannier B,
    5. Boutouyrie P,
    6. Marchais SJ,
    7. Mëtivier F
    : Mineral metabolism and arterial functions in end-stage renal disease: Potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 18: 613– 620, 2007
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Matias PJ,
    2. Ferreira C,
    3. Jorge C,
    4. Borges M,
    5. Aires I,
    6. Amaral T,
    7. Gil C,
    8. Cortez J,
    9. Ferreira A
    : 25-Hydroxyvitamin D3, arterial calcifications and cardiovascular risk markers in haemodialysis patients. Nephrol Dial Transplant 24: 611– 618, 2009
    OpenUrlCrossRefPubMed
  16. 16.↵
    Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl S1– S130, 2009
  17. 17.↵
    1. Bushinsky DA,
    2. Monk RD
    : Electrolyte quintet: Calcium. Lancet 352: 306– 311, 1998
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Matias P,
    2. Jorge C,
    3. Aires I,
    4. Lage H,
    5. Gil C,
    6. Gomes F,
    7. Arranhado E,
    8. Ferreira A
    : Brain natriuretic peptide levels predict morbidity and mortality in haemodialysis patients. Port J Nephrol Hypertens 23: 249– 255, 2009
    OpenUrl
  19. 19.↵
    1. Devereux RB,
    2. Alonso DR,
    3. Lutas EM,
    4. Gottlieb GJ,
    5. Campo E,
    6. Sachs I,
    7. Reichek N
    : Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol 57: 450– 458, 1986
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Hollis BW
    : Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: Implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr 135: 317– 322, 2005
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Sato T
    : Renal bioactivation of vitamin D and its key modulators. Clin Calcium 17: 686– 690, 2007
    OpenUrlPubMed
  22. 22.↵
    1. Lambert PW,
    2. Stern PH,
    3. Avioli RC,
    4. Brackett NC,
    5. Turner RT,
    6. Greene A,
    7. Fu IY,
    8. Bell NH
    : Evidence for extrarenal production of 1 alpha, 25-dihydroxyvitamin D in man. J Clin Invest 69: 722– 725, 1982
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Jean G,
    2. Terrat JC,
    3. Vanel T,
    4. Hurot JM,
    5. Lorriaux C,
    6. Mayor B,
    7. Chazot C
    : Evidence for persistent vitamin d 1-alpha-hydroxylation in hemodialysis patients: Evolution of serum 1,25-dihydroxycholecalciferol after 6 months of 25-hydroxycholecalciferol treatment. Nephron Clin Pract 110: c58– c65, 2008
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Dusso AS,
    2. Finch J,
    3. Brown A,
    4. Ritter C,
    5. Delmez J,
    6. Schreiner G,
    7. Slatopolsky E
    : Extrarenal production of calcitriol in normal and uremic humans. J Clin Endocrinol Metab 72: 157– 164, 1991
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Hewison M,
    2. Zehnder D,
    3. Bland R,
    4. Stewart PM
    : 1 Alpha-hydroxylase and the action of vitamin D. J Mol Endocrinol 25: 141– 148, 2000
    OpenUrlAbstract
  26. 26.↵
    1. Dusso AS,
    2. Brown AJ,
    3. Slatopolsky E
    : Vitamin D. Am J Physiol Renal Physiol 289: F8– F28, 2005
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Mosekilde L
    : Vitamin D and the elderly. Clin Endocrinol (Oxf) 62: 265– 281, 2005
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Lips P
    : Vitamin D physiology. Prog Biophys Mol Biol 92: 4– 8, 2006
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Jones G,
    2. Vriezen D,
    3. Lohnes D,
    4. Palda V,
    5. Edwards NS
    : Side-chain hydroxylation of vitamin D3 and its physiological implications. Steroids 49: 29– 53, 1987
    OpenUrlPubMed
  30. 30.↵
    1. Makin G,
    2. Lohnes D,
    3. Byford V,
    4. Ray R,
    5. Jones G
    : Target cell metabolism of 1,25-(OH)2D3 to calcitroic acid: Evidence for a pathway in kidney and bone involving 24-oxidation. Biochem J 262: 173– 180, 1989
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Ritter CS,
    2. Armbrecht HJ,
    3. Slatopolsky E,
    4. Brown AJ
    : 25-Hydroxyvitamin D3 suppresses PTH synthesis and secretion by bovine parathyroid cells. Kidney Int 70: 654– 659, 2006
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Aucella F,
    2. Scalzulli RP,
    3. Gatta G,
    4. Vigilante M,
    5. Carella AM,
    6. Stallone C
    : Calcitriol increases burst-forming unit-erythroid proliferation in chronic renal failure: A synergistic effect with r-HuEpo. Nephron Clin Pract 95: c121– c127, 2003
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Mathieu C,
    2. Jafari M
    : Immunomodulation by 1,25-dihydroxyvitamin D3: Therapeutic implications in hemodialysis and renal transplantation. Clin Nephrol 66: 275– 283, 2006
    OpenUrlPubMed
  34. 34.↵
    1. Seibert E,
    2. Levin NW,
    3. Kuhlmann MK
    : Immunomodulating effects of vitamin D analogs in hemodialysis patients. Hemodial Int 9[ Suppl 1]: S25– S29, 2005
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Targher G,
    2. Bertolini L,
    3. Padovani R,
    4. Zenari L,
    5. Scala L,
    6. Cigolini M,
    7. Arcaro G
    : Serum 25-hydroxyvitamin D3 concentrations and carotid artery intima-media thickness among type 2 diabetic patients. Clin Endocrinol (Oxf) 65: 593– 597, 2006
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Jean G,
    2. Terrat JC,
    3. Vanel T,
    4. Hurot JM,
    5. Lorriaux C,
    6. Mayor B,
    7. Chazot C
    : Daily oral 25-hydroxycholecalciferol supplementation for vitamin d deficiency in haemodialysis patients: Effects on mineral metabolism and bone markers. Nephrol Dial Transplant 23: 3670– 3676, 2008
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Saab G,
    2. Young DO,
    3. Gincherman Y,
    4. Giles K,
    5. Norwood K,
    6. Coyne DW
    : Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract 105: c132– c138, 2007
    OpenUrlPubMed
  38. 38.↵
    1. Foley RN,
    2. Parfrey PS,
    3. Sarnak MJ
    : Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32[ Suppl 3]: S112– S119, 1998
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Racek J,
    2. Králová H,
    3. Trefil L,
    4. Rajdl D,
    5. Eiselt J
    : Brain natriuretic peptide and N-terminal proBNP in chronic haemodialysis patients. Nephron Clin Pract 103: c162– c172, 2006
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Zeng C,
    2. Wei T,
    3. Jin L,
    4. Wang L
    : Value of B-type natriuretic peptide in diagnosing left ventricular dysfunction in dialysis-dependent patients. Intern Med J 36: 552– 557, 2006
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Levin ER,
    2. Gardner DG,
    3. Samson WK
    : Natriuretic peptides. N Engl J Med 339: 321– 328, 1998
    OpenUrlCrossRefPubMed
  42. 42.↵
    1. Nitta K,
    2. Kawashima A,
    3. Yumura W,
    4. Naruse M,
    5. Oba T,
    6. Kabaya T,
    7. Nihei H
    : Plasma concentration of brain natriuretic peptide as an indicator of cardiac ventricular function in patients on hemodialysis. Am J Nephrol 18: 411– 415, 1998
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Li YC,
    2. Qiao G,
    3. Uskokovic M,
    4. Xiang W,
    5. Zheng W,
    6. Kong J
    : Vitamin D: A negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol 89: 387– 392, 2004
    OpenUrlCrossRefPubMed
  44. 44.
    1. Lind L,
    2. Hanni A,
    3. Lithell H,
    4. Hvarfner A,
    5. Sorensen OH,
    6. Ljunghall S
    : Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-age men. Am J Hypertens 8: 894– 901, 1995
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology
Vol. 5, Issue 5
1 May 2010
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Cholecalciferol Supplementation in Hemodialysis Patients: Effects on Mineral Metabolism, Inflammation, and Cardiac Dimension Parameters
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Cholecalciferol Supplementation in Hemodialysis Patients: Effects on Mineral Metabolism, Inflammation, and Cardiac Dimension Parameters
Patrícia João Matias, Cristina Jorge, Carina Ferreira, Marília Borges, Inês Aires, Tiago Amaral, Célia Gil, José Cortez, Aníbal Ferreira
CJASN May 2010, 5 (5) 905-911; DOI: 10.2215/CJN.06510909

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Cholecalciferol Supplementation in Hemodialysis Patients: Effects on Mineral Metabolism, Inflammation, and Cardiac Dimension Parameters
Patrícia João Matias, Cristina Jorge, Carina Ferreira, Marília Borges, Inês Aires, Tiago Amaral, Célia Gil, José Cortez, Aníbal Ferreira
CJASN May 2010, 5 (5) 905-911; DOI: 10.2215/CJN.06510909
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Conclusions
    • Disclosures
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

Original Articles

  • Association of Polypharmacy with Kidney Disease Progression in Adults with CKD
  • The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function
  • Collectin11 and Complement Activation in IgA Nephropathy
Show more Original Articles

Mineral Metabolism and Bone Disease

  • Sclerostin and Dickkopf-1 in Renal Osteodystrophy
  • Chronic Kidney Disease Progression and Outcome According to Serum Phosphorus in Mild-to-Moderate Kidney Dysfunction
  • Associations between Serum Leptin Level and Bone Turnover in Kidney Transplant Recipients
Show more Mineral Metabolism and Bone Disease

Cited By...

  • Evaluation of responses to vitamin D3 (cholecalciferol) in patients on dialysis: a systematic review and meta-analysis
  • Ergocalciferol Supplementation in Hemodialysis Patients With Vitamin D Deficiency: A Randomized Clinical Trial
  • Associations Between Serum-Intact Parathyroid Hormone, Serum 25-Hydroxyvitamin D, Oral Vitamin D Analogs and Metabolic Syndrome in Peritoneal Dialysis Patients: A Multi-Center Cross-Sectional Study
  • Serum 25-Hydroxyvitamin D Level Is Associated With Arterial Stiffness, Left Ventricle Hypertrophy, and Inflammation in Newly Diagnosed Hypertension
  • Effects of Cholecalciferol on Functional, Biochemical, Vascular, and Quality of Life Outcomes in Hemodialysis Patients
  • Calcium Absorption Response to Cholecalciferol Supplementation in Hemodialysis
  • Vitamin D Status and Outcomes After Renal Transplantation
  • 25-Hydroxyvitamin D Response to Cholecalciferol Supplementation in Hemodialysis
  • High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial
  • Efficacy and safety of a short course of very-high-dose cholecalciferol in hemodialysis
  • The Fluid Study Protocol: A Randomized Controlled Study on the Effects of Bioimpedance Analysis and Vitamin D on Left Ventricular Mass in Peritoneal Dialysis Patients
  • Vitamin D Supplementation in Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Observational Studies and Randomized Controlled Trials
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals

© 2022 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire